Faculty Information - YOSHIDA Kazuhiko

（Last updated : 2026-08-12 15:44:20）

YOSHIDA Kazuhiko
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Associate Professor

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3.	Other	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. 2026/05
4.	Other	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
5.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
6.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
7.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
8.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
9.	Original article	Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations. 2026/03
10.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
11.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
12.	Original article	Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
13.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
14.	Original article	Renal parenchymal defects occasionally observed in non–well-differentiated perirenal liposarcomas unlike in well-differentiated types. 2025/11
15.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
16.	Case report	Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: Case report 2025/09/01
17.	Original article	Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
18.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
19.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
20.	Case report	Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases. 2025/08
21.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
22.	Original article	Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
23.	Other	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
24.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
25.	Other	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
26.	Other	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
27.	Other	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. 2025/05
28.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
29.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
30.	Original article	Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study. 2025/03
31.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
32.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
33.	Original article	Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
34.	Original article	Impact of tumor dissecting technique on trifecta achievement in patients requiring extended warm ischemia during robot-assisted partial nephrectomy. 2024/10/18
35.	Original article	Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
36.	Case report	Effectiveness of robot-assisted adrenalectomy for a giant adrenal hemangioma: A case report. 2024/09
37.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
38.	Original article	Comparison of surgical outcomes of robot‑assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single‑layer and double‑layer renorrhaphy. 2024/07/27
39.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
40.	Original article	Robot-assisted partial nephrectomy with selective artery clamping for renal cell carcinoma in horseshoe kidney. 2024/07
41.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
42.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
43.	Original article	Predicting recurrence after radical surgery for high‑risk renal cell carcinoma: Development and internal validation of the “TOWARDS” score. 2024/05
44.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
45.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
46.	Original article	Safety of docetaxel in a patient with metastatic castration-resistant prostate cancer after kidney transplantation: A case report. 2024/04
47.	Original article	Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
48.	Case report	Advanced renal cell carcinoma with Inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. 2024/03
49.	Original article	Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
50.	Original article	Prognostic value of the lung immune prognostic index on recurrence after radical surgery for high-risk renal cell carcinoma. 2024/02/14
51.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
52.	Original article	Clinical course of candidate renal tansplant recipients diagnosed with prostate cancer during pre-transplant screening test. 2024/01
53.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
54.	Original article	A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection. 2023/12
55.	Review article	Advances in molecular-targeted therapies of advanced urological cancers: focus on advanced renal cell carcinoma. 2023/12
56.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
57.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
58.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
59.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
60.	Case report	Long-time survival of a renal transplant recipient with metastatic mucinous tubular and spindle cell carcinoma: A case report. 2023/05
61.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
62.	Original article	Efficacy of combined pembrolizumab and pelvic radiotherapy for bladder cancer with rectal metastases. 2023/03
63.	Original article	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. 2023/03
64.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
65.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
66.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
67.	Original article	Analyses of operative time according to procedure phases during robot-assisted laparoscopic partial nephrectomy using the iPhone application “My Intuitives” 2022/11
68.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
69.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
70.	Original article	New longitudinal component of the RENAL nephrometry score for predicting the operative complexity in transperitoneal robot-assisted partial nephrectomy. 2022/06
71.	Original article	Surgical outcomes of robot-assisted laparoscopic partial nephrectomy for cystic renal cell carcinoma. 2022/06
72.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
73.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
74.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
75.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
76.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
77.	Original article	Comparison of surgical outcomes between enucleation and standard resection in robot-assisted partial nephrectomy for completely endophytic renal tumors through a 1:1 propensity score-matched analysis. 2021/12
78.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
79.	Original article	Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. 2021/12
80.	Original article	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2021/11
81.	Original article	Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma. 2021/11
82.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
83.	Original article	Greater renal function benefit from enucleation technique for more complex renal tumors in robot-assisted partial nephrectomy. 2021/10
84.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
85.	Original article	Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. 2021/10
86.	Original article	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
87.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
88.	Original article	Early dark cortical band sign on CT for differentiating clear cell renal cell carcinoma from fat poor angiomyolipoma and detecting peritumoral pseudocapsule. 2021/08
89.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
90.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
91.	Case report	Robot-assisted laparoscopic partial nephrectomy for allograft renal cell carcinoma: A case report. 2021/06
92.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
93.	Original article	Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
94.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
95.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
96.	Original article	Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. 2021/04
97.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
98.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
99.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
100.	Original article	Comparison of postoperative recovery after robot-assisted partialnephrectomy of T1 renal tumors through retroperitoneal ortransperitoneal approach: A Japanese single institutional analysis. 2021/02
101.	Original article	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. 2021/02
102.	Original article	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot‑assisted partial nephrectomy using enhanced MDCT. 2021/01
103.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
104.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
105.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
106.	Case report	Total nephroureterocystectomy and urethrectomy due to urothelial carcinoma associated with the BK polyomavirus infection after kidney transplantation: a case report with literature review. 2020/11
107.	Original article	Mid-term outcome of transarterial embolization of renal artery pseudoaneurysm and arteriovenous fistula after partial nephrectomy screened by early postoperative contrast-enhanced CT. 2020/09
108.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
109.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
110.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
111.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
112.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
113.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
114.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
115.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
116.	Original article	Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. 2020/01
117.	Original article	Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients. 2019/11
118.	Original article	Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. 2019/11
119.	Original article	Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions. 2019/08
120.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
121.	Original article	Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy carried out using the enucleation technique. 2019/07
122.	Original article	Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. 2019/07
123.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
124.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
125.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
126.	Original article	Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. 2019/04
127.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
128.	Original article	Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. 2019/02
129.	Original article	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. 2018/12
130.	Original article	Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
131.	Original article	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. 2018/09
132.	Original article	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
133.	Original article	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
134.	Original article	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. 2018/06
135.	Original article	Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
136.	Original article	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2017/12
137.	Original article	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. 2017/09
138.	Original article	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. 2017/09
139.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
140.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
141.	Original article	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. 2016/10
142.	Original article	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. 2016/09
143.	Original article	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. 2016/06
144.	Original article	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. 2015/12
145.	Original article	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. 2015/10
146.	Original article	Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for ≥T1b renal tumors. 2015/09
147.	Original article	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. 2015/04
148.	Original article	Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. 2014/12
149.	Other	The phenotype of repopulating B cell after rituximab therapy in kidney transplant patients. 2014/11
150.	Original article	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. 2014/06
151.	Original article	Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. 2014/05
152.	Case report	Cystic local recurrence of renal cell carcinoma after laparoscopic radical nephrectomy in a hemodialysis patient. 2014/03
153.	Original article	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off 2014/03
154.	Original article	The influence of RENAL nephrometry score on pre-ruptured pseudoaneurysm formation detected by computed tomography angiography in early postoperative period after minimally invasive partial nephrectomy. 2014/01
155.	Original article	Successful Kidney Transplantation for End-Stage Renal Disease in Marfan's Syndrome 2013/09
156.	Original article	The utility of monitoring serum KL-6 level for predicting the onset of mTOR inhibitors induced interstitial lung disease 2013/07
157.	Original article	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience 2013
Display 5 items
Display all(157)

■ Academic conference presentation

1.	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. （Poster notice，General） 2026/05/18
2.	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice，General） 2026/05/18
3.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
4.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （Poster notice，General） 2026/05/16
5.	Association of Serum Kidney Injury Molecule-1 with Treatment Response and Survival in Metastatic Renal Cell Carcinoma. （Speech，General） 2026/04/25
6.	Clinical Role of Upfront Cytoreductive Nephrectomy. （Speech，Panelist at Symposium/Workshop (Other)） 2026/04/25
7.	Real world data of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma: Multi-center retrospective study in Japan. （Speech，General） 2026/04/24
8.	Real-world experience with adjuvant pembrolizumab toxicities in renal cell carcinoma: A single-center experience at Tokyo Women's Medical University. （Speech，General） 2026/04/24
9.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
10.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
11.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （Poster notice，General） 2026/04/23
12.	Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
13.	Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma. （Poster notice，General） 2026/02/28
14.	Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma. （Poster notice，General） 2026/02/28
15.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
16.	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. （Poster notice，General） 2025/04/29
17.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
18.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
19.	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
20.	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. （Poster notice，General） 2025/04/26
21.	Clinical outcomes of repeat robot-assisted partial nephrectomy compared to repeat open partial nephrectomy. （Speech，General） 2025/03/23
22.	Predictive value of HLAMatchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after kidney transplantation-A Japanese single-center study. （Poster notice，General） 2024/11/14
23.	Greater impact of tumor dissecting technique on trifecta achievement in patients requiring extended warm ischemia during robotic-assisted partial nephrectomy. （Poster notice，General） 2024/05/06
24.	Patient and tumor profile differences for early and late recurrences following radical resection for high-risk renal cell carcinoma. （Poster notice，General） 2024/05/05
25.	Prognostic impact of lung immune prognostic index in recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2024/05/05
26.	Predicting recurrence after radical surgery for high-risk renal cell carcinoma: Development and Internal Validation of　“TOWARDS” score. （Poster notice，General） 2024/05/04
27.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
28.	Clinical course of candidate renal transplant recipients diagnosed with prostate cancer during pre-transplant screening test. （Poster notice，General） 2024/04/27
29.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
30.	Predicting recurrence after radical surgery for high-risk renal cell carcinoma: development and internal validation of "TOWARDS" score. （Poster notice） 2024/04/27
31.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
32.	BRCA mutation-positive prostate cancer at our hospital initial experience with olaparib in BRCA mutation-positive prostate cancer. （Poster notice，General） 2024/04/26
33.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
34.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
35.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
36.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
37.	Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. （Poster notice，General） 2024/04/26
38.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. （Poster notice，General） 2024/04/26
39.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. （Poster notice） 2024/04/25
40.	Comparison of surgical outcomes between robot-assisted and conventional laparoscopic adrenalectomy at Tokyo Women's Medical University Hospital. （Poster notice，General） 2024/04/25
41.	Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorraphy: Analyses of an experienced surgeon. （Speech，General） 2024/04/08
42.	Follow-up survey of candidate renal transplant recipients with prostate cancer diagnosed during the pre-transplant screening test. （Poster notice，General） 2023/08/25
43.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
44.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
45.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. （Poster notice，General） 2023/04/29
46.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
47.	Initial experiences of robot-assisted adrenalectomy. （Poster notice，General） 2023/04/22
48.	Medication states of up-front ARAT treatment for mHSPC in real-world practice. （Poster notice，General） 2023/04/21
49.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. （Speech，General） 2023/04/21
50.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. （Poster notice，General） 2023/04/21
51.	Circulation kinetics analysis using computed tomography of papillary renal cell carcinoma, chromophobe renal cell carcinoma, oncocytoma, and angiomyolipoma. （Poster notice） 2023/04/20
52.	Donor-derived cell-free DNA analysis is capable of detecting antibody-mediated rejection in one-year biopsy of kidney allograft. （Speech，General） 2023/04/20
53.	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. （Speech，General） 2023/04/20
54.	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. （Speech） 2023/04/20
55.	Our techniques for robot-assisted laparoscopic partial nephrectomy. （Speech，Panelist at Symposium/Workshop (Other)） 2023/04/20
56.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
57.	Outcomes of treatments for acute antibody-mediated rejection after kidney transplantation. （Speech，General） 2022/11/26
58.	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. （Poster notice，General） 2022/05/16
59.	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: Comparison with younger counterparts. （Poster notice，General） 2022/05/15
60.	Order of thrombectomy for management of renal cell carcinoma with inferior vena cava thrombus. （Poster notice，General） 2022/05/15
61.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
62.	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. （Poster notice，General） 2022/05/13
63.	C-reactive protein kinetics to predict recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2022/05/13
64.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
65.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
66.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
67.	Comparison of surgical outcomes in robot-assisted partial nephrectomy for completely endophytic renal tumors between enucleation and standard resection through a 1:1 propensity score–matched analysis. （Poster notice） 2021/09/12
68.	Retzius-sparing robot-assisted radical prostatectomy in a renal transplant recipient. （Poster notice，General） 2021/07/25
69.	Medication adherence and treatment outcome in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. （Speech，General） 2020/12/24
70.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. （Speech，General） 2020/12/23
71.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2020/12/23
72.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2020/12/23
73.	Safety and efficacy of nivolumab for patients with chronic kidney disease. （Speech，General） 2020/12/23
74.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. （Speech，General） 2020/12/23
75.	Therapeutic benefit of lymphadenectomy during radical nephroureterectomy for elderly patients with upper tract urothelial carcinoma. （Speech，General） 2020/12/23
76.	Reduced risk of new occurrence or progression of sarcopenia by robot-assisted radical cystectomy compared to the open procedure. （Speech，General） 2020/12/22
77.	Retroperitoneal approach is better quality of recovery than transperitoneal approach after robot-assisted partial nephrectomy. （Poster notice，General） 2020/12/22
78.	Trifecta outcomes of robot-assisted laparoscopic partial nephrectomy compared to conventional partial nephrectomy. （Speech，General） 2020/12/22
79.	The 34th Congress of Japanese Society of Endourology （Speech，General） 2020/11/19
80.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. （Poster notice，General） 2020/10/01
81.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. （Speech，General） 2020/07/17
82.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. （Speech，General） 2020/07/17
83.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. （Speech，General） 2020/07/17
84.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. （Poster notice，General） 2020/07/17
85.	Renal cell carcinoma in end-stage renal disease exhibits specific molecular alterations corresponding to their histopathology. （Poster notice，General） 2019/10/18
86.	Renal cell carcinoma in end-stage renal disease has specific molecular alterations corresponding to the histopathology. （Poster notice，General） 2019/09/27
87.	Clinical future of mucinous tubular and spindle cell carcinoma of the kidney. （Poster notice，General） 2019/08/17
88.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical recurrence in patients with prostate cancer treated with radiotherapy. （Poster notice，General） 2019/05/06
89.	Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy performed using the enucleation technique. （Poster notice，General） 2019/05/04
90.	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib herapy for metastatic renal cell carcinoma. （Poster notice，General） 2019/05/04
91.	Long-term follow-up of renal function and development of chronic kidney disease after partial nephrectomy. （Poster notice，General） 2019/05/04
92.	Presence of peritumoral pseudocapsules detected based on findings from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. （Poster notice，General） 2019/05/04
93.	Association of immune-related adverse events with prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2019/05/03
94.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy, using enhanced CT. （Poster notice，General） 2019/05/03
95.	Robotic surgeries for urological malignancies in renal transplant recipients （Speech，Special/Invited Lecture） 2018/10/05
96.	Effect of luteinizing hormone-eleasing hormone antagonist on testosterone recovery after neoadjuvant therapy with or without adjuvant androgen deprivation and radiotherapy for localized prostate cancer. （Poster notice，General） 2018/05/21
97.	Superior efficacy of degarelix as neoadjuvant hormone therapy in control of acute genitourinary toxicity associated with radiation therapy for prostate cancer compared to LHRH agonist; A propensity-score matching analysis. （Poster notice，General） 2018/05/21
98.	Clinicopathological analysis of prostate cancer in patients with renal transplant recipients. （Poster notice，General） 2018/05/20
99.	Effect of early-period relative dose intensity in first-line sunitinib therapy with a 2-weeks-on and 1-week-off regimen for metastatic renal cell carcinoma. （Poster notice，General） 2018/05/20
100.	Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. （Poster notice，General） 2018/05/20
101.	Comparison of kidney function in the early postoperative period between a transperitoneal versus retroperitoneal robot-assisted laparoscopic partial nephrectomy for posterior renal tumor : A propensity score-matched study. （Poster notice，General） 2018/05/19
102.	Prognostic value of the glasgow Prognostic score for patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. （Poster notice，General） 2018/05/19
103.	Post Adrenalectomy renal function in patients with primary aldosteronism. （Poster notice，General） 2018/05/18
104.	Predictive factors for immediate progression after nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2018/04/20
105.	Adaptor protein CRK regulates ErbB2 expression in exosome and promotes tumor progression and metastasis of bladder cancer. （Poster notice） 2018/04/19
106.	Usefulness of the modified Glasgow Prognostic Score (mGPS) in patients with castration- sensitive prostate cancer: muti- institutional study. （Poster notice） 2018/04/19
107.	Higher risk of recurrence at extraregional nodes after radical nephroureterectomy in patients with left than in patients with right ureteral cancer （Speech，General） 2017/05/15
108.	Clinicopathological characteristics of patients with acquiredcystic disease-associated renal cell carcinoma: Central pathology results according to the 2016 WHO classification in a multi-institutional study （Speech） 2017/05/14
109.	Impact of surgeon's experience on occurrence of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2016/11/11
110.	Lymphatic metastases from the urothelial carcinoma of the left lower ureter spreads more extensively at higher incidence than the tumors of the right side. （Speech） 2016/04/24
111.	The relationship between the timing of maximum tumor shrinkage during 1st-line targeted therapy and overall survival of patients with metastatic renal cell carcinoma. （Poster notice，General） 2015/05/18
112.	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence in patients with upper/middle ureteral cancer. （Poster notice，General） 2015/05/15
113.	Template-based lymphadenectomy reduced the risk of regional node recurrence in patients with renal pelvic cancer. （Poster notice，General） 2014/05/20
114.	Risk factors and management of unruptured renal artery pseudoaneurysms immediately after laparoscopic partial Nephrectomy. （Speech，General） 2014/05/19
115.	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. （Poster notice，General） 2014/05/17
116.	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease （Poster notice，General） 2013/05/20
117.	Usefulness of temporary inferior vena cava filter in preventing intraoperative pulmonary embolism for patients with renal cell carcinoma extending into inferior vena cava thrombus （Poster notice，General） 2013/05/07
118.	Enhanced CT after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm （Poster notice，General） 2013/05/06
119.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis - Multi-institutional prospective study - （Speech，General） 2013/05/06
120.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis （Speech，General） 2013/03/18
Display 5 items
Display all(120)

■ Education

〔Doctoral course〕〔Doctorial Course〕, Tokyo Women's Medical University, Completed